- Home
- MKZR vs BIVI Comparison
MKZR vs BIVI Comparison
Compare MKZR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- BIVI
- Stock Information
- Founded
- MKZR 2012
- BIVI 2013
- Country
- MKZR United States
- BIVI United States
- Employees
- MKZR N/A
- BIVI N/A
- Industry
- MKZR
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- BIVI Health Care
- Exchange
- MKZR Nasdaq
- BIVI Nasdaq
- Market Cap
- MKZR 10.3M
- BIVI 11.9M
- IPO Year
- MKZR N/A
- BIVI N/A
- Fundamental
- Price
- MKZR $5.78
- BIVI $1.74
- Analyst Decision
- MKZR
- BIVI
- Analyst Count
- MKZR 0
- BIVI 0
- Target Price
- MKZR N/A
- BIVI N/A
- AVG Volume (30 Days)
- MKZR 69.1K
- BIVI 510.1K
- Earning Date
- MKZR 09-19-2025
- BIVI 08-15-2025
- Dividend Yield
- MKZR 38.99%
- BIVI N/A
- EPS Growth
- MKZR N/A
- BIVI N/A
- EPS
- MKZR N/A
- BIVI N/A
- Revenue
- MKZR $23,037,348.00
- BIVI N/A
- Revenue This Year
- MKZR N/A
- BIVI N/A
- Revenue Next Year
- MKZR N/A
- BIVI N/A
- P/E Ratio
- MKZR N/A
- BIVI N/A
- Revenue Growth
- MKZR 52.64
- BIVI N/A
- 52 Week Low
- MKZR $3.89
- BIVI $1.42
- 52 Week High
- MKZR $55.00
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- MKZR 50.44
- BIVI 29.37
- Support Level
- MKZR $4.76
- BIVI $1.54
- Resistance Level
- MKZR $6.40
- BIVI $1.68
- Average True Range (ATR)
- MKZR 0.42
- BIVI 0.14
- MACD
- MKZR 0.12
- BIVI 0.25
- Stochastic Oscillator
- MKZR 62.01
- BIVI 84.21
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.